{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 477235538
| IUPAC_name = 3,4-Dichloro-''N''-[(1''R'',2''R'')-2-(dimethylamino)cyclohexyl]-''N''-methylbenzamide
| image = U-47700 fixedstructure.svg
<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA =
| legal_UK = PSA
| legal_US = Schedule I 
| legal_status = Illegal in Finland, Sweden
| routes_of_administration =
<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
<!--Identifiers-->
| CAS_number_Ref =
| CAS_number = 82657-23-6
| ATC_prefix = 
| ATC_suffix =
| PubChem =  13544016
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 23113403
| ChEMBL = 277572
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6IY4WX208T

<!--Chemical data-->
| C=16 | H=22 | Cl=2 | N=2 | O=1
| molecular_weight =
| smiles = ClC1=C(C=CC(=C1)C(=O)N(C)[C@@H]2CCCC[C@H]2N(C)C)Cl
| StdInChI = 1S/C16H22Cl2N2O/c1-19(2)14-6-4-5-7-15(14)20(3)16(21)11-8-9-12(17)13(18)10-11/h8-10,14-15H,4-7H2,1-3H3/t14-,15-/m1/s1
| StdInChIKey = JGPNMZWFVRQNGU-HUUCEWRRSA-N
}}

'''U-47700''' is an [[opioid]] [[analgesic]] drug developed by a team at [[Upjohn]] in the 1970s<ref>{{cite web | url=https://patents.google.com/patent/US4098904 | title=Patent US4098904 - Analgesic N-(2-aminocycloaliphatic)benzamides | date=4 July 1978 | author=Jacob Szmuszkovicz}}</ref> that has around 7.5 x the potency of [[morphine]] in animal models.<ref>{{cite journal|first1=B. Vernon|last1=Cheney|first2=Jacob|last2=Szmuszkovicz|first3=Robert A.|last3=Lahti|first4=Dominic A.|last4=Zichi|title=Factors affecting binding of ''trans''-''N''-[2-(methylamino)cyclohexyl]benzamides at the primary morphine receptor|url=http://pubs.acs.org/doi/abs/10.1021/jm00150a017|journal=Journal of Medicinal Chemistry|date=December 1985|pages=1853–1864|volume=28|issue=12|doi=10.1021/jm00150a017|pmid=2999404}}</ref><ref>{{cite journal|first1=N. J.|last1=Harper|first2=G. B. A.|last2=Veitch|first3=D. G.|last3=Wibberley|title=1-(3,4-Dichlorobenzamidomethyl)cyclohexyldimethylamine and related compounds as potential analgesics|url=http://pubs.acs.org/doi/abs/10.1021/jm00257a012|journal=Journal of Medicinal Chemistry|date=November 1974|pages=1188–1193|volume=17|issue=11|doi=10.1021/jm00257a012|pmid=4416926}}</ref><ref>{{cite journal|first1=Jacob|last1=Szmuszkovicz|first2=Philip F.|last2=Von Voigtlander|title=Benzeneacetamide Amines: Structurally Novel Non-mµ Opioids|url=http://pubs.acs.org/doi/abs/10.1021/jm00352a005|pmid=6128415|journal=Journal of Medicinal Chemistry|date=October 1982|issn=0022-2623|pages=1125–1126|volume=25|issue=10|doi=10.1021/jm00352a005}}</ref>

U-47700 is a structural isomer of the earlier opioid [[AH-7921]]<ref>{{cite journal|first1=R. T.|last1=Brittain|first2=D. N.|last2=Kellett|first3=M. L.|last3=Neat|first4=R.|last4=Stables|title=Proceedings: Anti-nociceptive effects in ''N''-substituted cyclohexylmethylbenzamides.|journal=British Journal of Pharmacology|date=September 1973|issn=0007-1188|pages=158P–159P|volume=49|issue=1|pmid=4207044|pmc=1776456|doi=10.1111/j.1476-5381.1973.tb08279.x}}</ref> and the result of a great deal of work elucidating the [[quantitative structure–activity relationship]] of the scaffold. Upjohn looked for the key [[moiety (chemistry)|moieties]] which gave the greatest activity<ref>{{cite book|first1=Erik T.|last1=Michalson|first2=Jacob|last2=Szmuszkovicz|title=Medicinal agents incorporating the 1,2-diamine functionality|url=https://link.springer.com/chapter/10.1007/978-3-0348-9146-2_6|publisher=Birkhäuser Basel|journal=Progress in Drug Research|date=1989|isbn=9783034891462|pages=135–149|series=Progress in Drug Research|doi=10.1007/978-3-0348-9146-2_6|pmid=2687936}}</ref> and posted over a dozen patents on related compounds, each optimizing one moiety<ref>{{cite web | url=https://patents.google.com/patent/US3258489 | title=Patent US US3258489 - N-(1-aminocyclohexylmethyl)anilines and N-(1-nitrocyclohexylmethyl)anilines | date=28 June 1966 | author=Darrell D. Mullins}}</ref><ref>{{cite web | url=https://patents.google.com/patent/US3975443 | title=Patent US3975443 - 1-(3,4-dichlorobenzamidomethyl)-cyclohexyldimethylamine | date=17 August 1976 | author1=Norman James Harper | author2=George Bryan Austin Veitch}}</ref><ref>{{cite web | url=https://patents.google.com/patent/US3499033 | title=Patent US3499033 - Ethers of α-phenyl-2-aminocycloalkanemethanols | date=3 March 1970 | author=Jacob Szmuszkovicz Kalamazoo}}</ref><ref>{{cite web | url=https://patents.google.com/patent/US3510492 | title=Patent US3510492 - 2-anilino and 2-anilinomethyl cycloalkylamines | date=5 May 1970 | author=Jacob Szmuszkovicz}}</ref><ref>{{cite web | url=https://patents.google.com/patent/US3647804 | title=Patent US3647804 - Cycloalkanecarboxamides | date=7 March 1972 | author1=Ronald H. Rynbrandt | author2=Louis L. Skaletzky}}</ref><ref>{{cite web | url=https://patents.google.com/patent/US3825595 | title=Patent US3825595 - N-cyclopentyl-N-2-hydroxyalkyl-ring-substituted benzamides | date=23 July 1974 | author=W. Roll}}</ref><ref>{{cite web | url=https://patents.google.com/patent/US4049663 | title=Patent US4049663 - Ethylene diamine derivatives | date=20 September 1977 | author1=Norman James Harper | author2=George Bryan Austin Veitch}}</ref><ref>{{cite web | url=https://patents.google.com/patent/US4463013 | title=Patent US4463013 - Oxygen substituted amino-cyclohexyl-benzeneacetamides and -benzamides as water diuretic drugs | date=9 April 1982 | author1=Robert J. Collins | author2=Lester J. Kaplan | author3=James H. Ludens | author4=Philip F. Von Voigtlander}}</ref> until they discovered that U-47700 was the most active.<ref>{{cite book|first1=Alan F.|last1=Casy|first2=Robert T.|last2=Parfitt|title=Miscellaneous Groups of Analgesics|url=https://link.springer.com/chapter/10.1007/978-1-4899-0585-7_11|publisher=Springer US|journal=Opioid Analgesics|date=1986|isbn=9781489905857|pages=385–403|doi=10.1007/978-1-4899-0585-7_11}}</ref>

U-47700 became the lead compound of selective kappa-opioid receptor ligands such as [[U-50488]], U-51754 (containing a single [[methylene spacer]] difference) and [[U-69,593]], which share very similar structures.<ref>{{cite journal|first1=Jacob|last1=Szmuszkovicz|first2=Shikai|last2=Zhao|first3=Michael J.|last3=Totleben|first4=Stephen A.|last4=Mizsak|title=Phenanthridone Analogs of the Opiate Agonist U-47,700 in the ''trans''-1,2-Diaminocyclohexane Benzamide Series|url=https://www.heterocycles.jp/newlibrary/libraries/abst/07731|journal=Heterocycles|volume=52|issue=1|pages=325–332|doi=10.3987/com-99-s27|first5=Jeremiah P.|last5=Freeman}}</ref><ref name="NIDA">{{cite journal|first1=G.|last1=Loew|first2=J.|last2=Lawson|first3=L.|last3=Toll|first4=G.|last4=Frenking|title=Structure activity studies of two classes of β-amino-amides: the search for kappa-selective opioids|url=https://archives.drugabuse.gov/pdf/monographs/90.pdf|journal=NIDA Research Monograph|date=1988|issn=1046-9516|pages=144–151|volume=90|pmid=2855852|first5=I.|last5=Berzetei-Gurske|first6=W.|last6=Polgar}}</ref> Although not used medically, the selective kappa ligands are used in research.<ref>{{cite book|first1=Jacob|last1=Szmuszkovicz|title=U-50,488 and the к receptor: A personalized account covering the period 1973 to 1990|url=https://link.springer.com/chapter/10.1007%2F978-3-0348-8730-4_4|publisher=Birkhäuser Basel|journal=Progress in Drug Research|date=1999|isbn=9783034887304|doi=10.1007/978-3-0348-8730-4_4|pages=167–195|series=Progress in Drug Research}}</ref><ref>{{cite journal|first1=S. Yu|last1=Tsibulnikov|first2=L. N.|last2=Maslov|first3=A. V.|last3=Mukhomedzyanov|first4=A. V.|last4=Krylatov|title=Prospects of Using of κ-Opioid Receptor Agonists U-50,488 and ICI 199,441 for Improving Heart Resistance to Ischemia/Reperfusion|url=https://link.springer.com/article/10.1007/s10517-015-3057-8|journal=Bulletin of Experimental Biology and Medicine|date=October 2015|issn=1573-8221|pages=718–721|volume=159|issue=6|doi=10.1007/s10517-015-3057-8|pmid=26519268|first5=M. R.|last5=Tsibulnikova|first6=Yu B.|last6=Lishmanov}}</ref>

== Side effects ==

U-47700 has never been studied on humans, but would be expected to produce effects similar to those of other potent opioid agonists, including strong analgesia, sedation, euphoria, constipation, itching and respiratory depression which could be harmful or fatal.<ref>{{cite web | url=http://www.nbcdfw.com/news/local/New-Synthetic-Opioid-Surfaces-in-North-Texas-371528161.html | title=New Synthetic Opioid Surfaces in North Texas | publisher=NBCDFW | date=9 March 2016 | author=Todd L. Davis}}</ref><ref>{{cite journal|first1=Matthew J.|last1=Jones|first2=Bradley S.|last2=Hernandez|first3=Gregory C.|last3=Janis|first4=Samuel J.|last4=Stellpflug|title=A case of U-47700 overdose with laboratory confirmation and metabolite identification|url=http://www.tandfonline.com/doi/full/10.1080/15563650.2016.1209767|journal=Clinical Toxicology|date=2016|issn=1556-3650|pages=1–5|volume=55|issue=|pmid=27549165|doi=10.1080/15563650.2016.1209767}}</ref><ref>{{cite journal|first1=K.|last1=Domanski|first2=K. C.|last2=Kleinschmidt|first3=J. M.|last3=Schulte|first4=S.|last4=Fleming|title=Two cases of intoxication with new synthetic opioid, U-47700|url=http://www.tandfonline.com/doi/full/10.1080/15563650.2016.1209763|journal=Clinical Toxicology|date=2016|issn=1556-3650|pages=1–5|volume=55|issue=|pmid=27432224|doi=10.1080/15563650.2016.1209763|first5=C.|last5=Frazee|first6=A.|last6=Menendez|first7=K.|last7=Tavakoli}}</ref><ref>{{cite journal|first1=Xiulu|last1=Ruan|first2=Srinivas|last2=Chiravuri|first3=AlanD.|last3=Kaye|title=Comparing fatal cases involving U-47700|url=https://link.springer.com/article/10.1007/s12024-016-9795-8|journal=Forensic Science, Medicine, and Pathology|date=September 2016|issn=1547-769X|pages=369–371|volume=12|issue=3|doi=10.1007/s12024-016-9795-8|pmid=27421264}}</ref><ref>{{cite journal|first1=Simon P.|last1=Elliott|first2=Simon D.|last2=Brandt|first3=Christopher|last3=Smith|title=The first reported fatality associated with the synthetic opioid 3,4-dichloro-''N''-[2-(dimethylamino)cyclohexyl]-''N''-methylbenzamide (U-47700) and implications for forensic analysis|url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1984/full|journal=Drug Testing and Analysis|date=August 2016|issn=1942-7611|pages=875–879|volume=8|issue=8|doi=10.1002/dta.1984|pmid=27232154}}</ref><ref>{{cite journal|first1=Patil|last1=Armenian|first2=Alexander|last2=Olson|first3=Andres|last3=Anaya|first4=Alicia|last4=Kurtz|title=Fentanyl and a Novel Synthetic Opioid U-47700 Masquerading as Street "Norco" in Central California: A Case Report|url=http://www.sciencedirect.com/science/article/pii/S019606441630292X|journal=Annals of Emergency Medicine|doi=10.1016/j.annemergmed.2016.06.014|pmid=27473610|first5=Rawnica|last5=Ruegner|first6=Roy R.|last6=Gerona|volume=69|pages=87–90}}</ref><ref>{{cite journal|first1=Anders|last1=Helander|first2=Matilda|last2=Bäckberg|title=New Psychoactive Substances (NPS) – the Hydra monster of recreational drugs|url=http://www.tandfonline.com/doi/full/10.1080/15563650.2016.1217003|journal=Clinical Toxicology|date=2016|issn=1556-3650|pmid=27549399|doi=10.1080/15563650.2016.1217003|pages=1–3}}</ref> Tolerance and dependence would be expected to develop.<ref>{{cite journal|first1=Andreas|last1=Kimergård|first2=Torben|last2=Breindahl|first3=Peter|last3=Hindersson|first4=Paolo|last4=Deluca|title=Tampering of opioid analgesics: a serious challenge for public health?|url=http://onlinelibrary.wiley.com/doi/10.1111/add.13436/full|journal=Addiction|date=October 2016|issn=1360-0443|pages=1701–1702|volume=111|issue=10|doi=10.1111/add.13436|pmid=27273814}}</ref>

=== Deaths ===

Combined consumption of U-47700 and [[fentanyl]] caused one fatality in Belgium.<ref>{{cite journal|first1=Vera|last1=Coopman|first2=Peter|last2=Blanckaert|first3=Geert|last3=Van Parys|first4=Serge|last4=Van Calenbergh|title=A case of acute intoxication due to combined use of fentanyl and 3,4-dichloro-''N''-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700)|url=http://www.sciencedirect.com/science/article/pii/S0379073816302006|journal=Forensic Science International|date=September 2016|pages=68–72|volume=266|doi=10.1016/j.forsciint.2016.05.001|pmid=27235591|first5=Jan|last5=Cordonnier}}</ref><ref>{{cite web | url=http://deredactie.be/cm/vrtnieuws/binnenland/1.2558454 | title=Twee doden in België door overdosis met fentanylpleisters | publisher=Deredactie | date=29 January 2016 | language=nl}}</ref> 17 opioid overdoses and several deaths in the United States had initially been associated with U-47700 in April 2016,<ref>{{cite news|first1=Susan|last1=Zalkind|title=Synthetic opiate makers stay step ahead of US drug laws as overdose cases rise|url=https://www.theguardian.com/world/2016/apr/11/synthetic-opiates-drug-laws-w-18-fentanyl|newspaper=The Guardian|date=11 April 2016|issn=0261-3077}}</ref> as of September 2016 at least 15 fatalities were confirmed.<ref>{{cite news | url=http://bigstory.ap.org/article/c36bdfeac0a448d881c1fbddd18dab6a/new-synthetic-drug-u-47700-has-states-rushing-stop-spread | title=New synthetic drug U-47700 has states rushing to stop spread | date=6 June 2016 | agency=Associated Press | author=Bill Draper}}</ref><ref>{{cite journal|first1=Aaron|last1=Schneir|first2=Imir G.|last2=Metushi|first3=Christian|last3=Sloane|first4=David J.|last4=Benaron|title=Near death from a novel synthetic opioid labeled U-47700: emergence of a new opioid class|url=http://www.tandfonline.com/doi/full/10.1080/15563650.2016.1209764|journal=Clinical Toxicology|date=2016|issn=1556-3650|pages=1–4|volume=55|issue=|pmid=27448790|doi=10.1080/15563650.2016.1209764|first5=Robert L.|last5=Fitzgerald}}</ref><ref>{{cite journal|first1=Amanda L. A.|last1=Mohr|first2=Melissa|last2=Friscia|first3=Donna|last3=Papsun|first4=Sherri L.|last4=Kacinko|title=Analysis of Novel Synthetic Opioids U-47700, U-50488 and Furanyl Fentanyl by LC–MS/MS in Postmortem Casework|url=https://jat.oxfordjournals.org/content/early/2016/09/01/jat.bkw086|journal=Journal of Analytical Toxicology|date=2016|issn=1945-2403|pmid=27590036|doi=10.1093/jat/bkw086|first5=David|last5=Buzby|first6=Barry K.|last6=Logan|volume=40|pages=709–717}}</ref><ref>{{Cite web|title=19 Recent Deaths Associated With Synthetic Opioids; State Officials Urge Awareness|work=NC Department of Health and Human Services|date=24 March 2016|url=https://www.ncdhhs.gov/news/press-releases/19-recent-deaths-associated-synthetic-opioids-state-officials-urge-awareness}}</ref><ref name="DEA">{{Cite web|title=Proposed Rule: Schedules of Controlled Substances: Temporary Placement of U-47700 Into Schedule I|author=Drug Enforcement Administration (DEA)|publisher=Federal Register|date=7 September 2016|url=https://www.federalregister.gov/documents/2016/09/07/2016-21477/schedules-of-controlled-substances-temporary-placement-of-u-47700-into-schedule-i}}</ref>

U-47700 was found in combination with fentanyl during the autopsy of the American guitarist [[Prince (musician)|Prince]] in 2016.<ref>{{cite web|url=https://www.forbes.com/sites/davidkroll/2016/11/30/furanyl-fentanyl-joins-u-47700-as-the-second-illicit-opioid-dea-banned-in-november/|title=Furanyl Fentanyl Joins U-47,700 As The Second Illicit Opioid Banned By DEA In November}}</ref>

== Legal status ==

Following its sale as a [[designer drug]], U-47700 was made illegal in Sweden on January 26, 2016.<ref>{{cite web | url=https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2015/november/31-nya-amnen-kan-klassas-som-narkotika-eller-halsofarlig-vara/ | title=31 nya ämnen kan klassas som narkotika eller hälsofarlig vara | publisher=Folkhälsomyndigheten | language=sv | date=November 2015}}</ref>

U-47700 was emergency scheduled in Ohio on May 3, 2016 by [[executive order]] of Governor [[John Kasich]].<ref>{{cite web | url=http://governor.ohio.gov/Portals/0/pdf/executiveOrders/Executive%20Order%202016-01K.pdf | title=Executive Order 2016-01K | publisher=Governor of Ohio | date=May 3, 2016 | author=John R. Kasich}}</ref>

U-47700 was emergency scheduled in Florida on September 27, 2016 by an emergency rule of Florida Attorney General Pam Bondi.<ref>{{Cite web|url=http://www.myfloridalegal.com/newsrel.nsf/newsreleases/65BA140203BABF4A8525803B006709D3|title=News Release - Attorney General Bondi Outlaws Deadly Synthetic Drug|website=www.myfloridalegal.com|access-date=9-27-2016}}</ref>

Responding to a perceived threat to public health and safety, the U.S. Drug Enforcement Administration has placed U-47700 into Schedule 1 of the Controlled Substances Act, effective November 14, 2016.<ref>{{cite web|url=https://www.dea.gov/divisions/hq/2016/hq111016.shtml|title=46 confirmed deaths linked to dangerous opioid in ’15 and ’16 spark emergency action |publisher=DEA | date=November 11, 2016 | author=DEA Public Affairs}}</ref>

U-47700 was placed into Schedule 1 of South Dakota's Controlled Substance Schedule. It was signed by Governor [[Dennis Daugaard|Daugaard]] on February 9, 2017.<ref>{{cite web|url=http://sdlegislature.gov/docs/legsession/2017/Bills/HB1041P.pdf|title=House Bill No. 1041|publisher=Governor Dauggard of South Dakota|author=South Dakota Legislature}}</ref>

==See also==
* [[Spiradoline]]
* [[U-69,593]]
* [[U-77891]]

== References ==
{{Reflist|2}}

{{Opioid receptor modulators}}

[[Category:Synthetic opioids]]
[[Category:Benzamides]]
[[Category:Mu-opioid agonists]]
[[Category:Amines]]
[[Category:Chloroarenes]]
[[Category:Designer drugs]]